Health & Medical · Week of Nov 2, 2026
Q3 results bring raised guidance, CVS plans split: health week
Third-quarter reports dominated, with Waters, Caris, and Shoulder Innovations raising 2026 guidance, while CVS Health set out plans to split in two.
Earnings filled most of the week. Waters Corporation, Caris Life Sciences and Shoulder Innovations each reported third-quarter 2026 results and raised full-year guidance. Waters says organic revenue grew 9% and it lifted its total reported revenue outlook by $43 million at the midpoint. Caris says revenue rose 27% on higher clinical case volume, and Shoulder Innovations says net revenue rose 38%. GRAIL reported 24% growth in Galleri test volume alongside a net loss of $103.6 million, and Community Healthcare Trust held its quarterly dividend at $0.33 per share.
Regulatory and corporate-structure news ran alongside the numbers. GRAIL says it expects an FDA decision on Galleri by early Q1 2027 after a favorable advisory committee vote. Shoulder Innovations reported an FDA 510(k) clearance for its N-22 humeral head. CVS Health announced plans to separate into two publicly traded companies by the first half of 2028. Accuray approved a 1-for-40 reverse stock split to address Nasdaq's minimum bid price requirement. Waters also announced the acquisition of MOBILion Systems.
Waters Corporation
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters Corporation reported third quarter 2026 revenue of $1.767 billion and adjusted EPS of $4.10, up 21%, and raised full-year guidance to $6.479 billion to $6.497 billion in total reported revenue. The company also said it has acquired MOBILion Systems, Inc., a developer of SLIM high-resolution ion mobility separation technology.
Caris Life Sciences
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year, and net income of $15.3 million, with about 61,500 clinical cases completed. The company raised full-year 2026 revenue guidance to $1.04 to $1.05 billion, though it reported free cash flow of $(39.7) million for the quarter.
GRAIL, Inc.
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL reported third quarter 2026 total revenue of $37.5 million and a net loss of $103.6 million, with Galleri test volume up about 24% to more than 56,000 tests. The company says an FDA advisory panel voted in favor of approving Galleri in September and it anticipates an FDA decision by early Q1 2027.
Shoulder Innovations
Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook
Shoulder Innovations reported third quarter 2026 net revenue of $16.2 million, up 38%, and raised full-year guidance to $68 million to $70 million. The company also reported FDA 510(k) clearance for the N-22 humeral head and a patent litigation settlement with Catalyst OrthoScience Inc.
Community Healthcare Trust Incorporated
Community Healthcare Trust Announces Results for the Three Months Ended September 30, 2026
Community Healthcare Trust reported third-quarter net income of about $3.1 million, or $0.09 per diluted share, and FFO of $0.54 per diluted share, and declared a $0.33 quarterly dividend payable November 25, 2026. The company says it has four properties under definitive purchase agreements for about $99.0 million, with closings expected from the fourth quarter of 2026 through early 2028.
CVS Health
CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare
CVS Health said it intends to separate into two publicly traded companies: a healthcare solutions company including Aetna, CVS Caremark and Oak Street Health, and CVS Pharmacy with approximately 9,000 pharmacies and MinuteClinic. The company expects completion in the first half of 2028, subject to conditions including final board approval and confirmation of tax-free treatment.
The Michael J. Fox Foundation for Parkinson's Research; Medtronic
Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
The Michael J. Fox Foundation and Medtronic launched an education initiative on deep brain stimulation for people with Parkinson's and their caregivers, available at michaeljfox.org/dbs. MJFF says it keeps editorial oversight of the materials, which Medtronic funds as premier partner.
Accuray Incorporated
Accuray Announces 1-for-40 Reverse Stock Split
Accuray said its board approved a 1-for-40 reverse stock split, effective November 9, 2026, reducing outstanding shares from about 120.2 million to about 3.0 million. The company says the move is intended to help it regain compliance with Nasdaq's minimum bid price requirement.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Insights Emerge reporting.